Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 4, 2023 4:05 PM EDTMultiple data readouts anticipated in 2023 from ongoing Phase 2 programsin hepatitis B and D, and influenza
Industry veteran Dr. Marianne De Backer assumes CEO position prepared to lead Company through next phase of growth
 $2.3 billion in cash, cash equivalents, and investments as of March 31, 2023Â
SAN FRANCISCO, May 04, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2023.
Vir is at an exciting inflection... More
